Cargando…

Patient-reported outcomes in schizophrenia patients treated with once-monthly extended-release risperidone in a long-term clinical study

PURPOSE: RBP-7000 (PERSERIS™) is a once-monthly subcutaneous extended-release risperidone formulation approved by the United States Food and Drug Administration for the treatment of schizophrenia in adults. The objective of this study was to describe the long-term impact of RBP-7000 on health-relate...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dhanda, Rahul, Varghese, Della, Nadipelli, Vijay R, Fava, Maurizio, Joshi, Namita, Solem, Caitlyn T, Graham, James A, Learned, Susan M, Heidbreder, Christian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2019
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6612993/ https://www.ncbi.nlm.nih.gov/pubmed/31308636 http://dx.doi.org/10.2147/PPA.S202173

Ejemplares similares

Patient-centered Outcomes in Participants of a Buprenorphine Monthly Depot (BUP-XR) Double-blind, Placebo-controlled, Multicenter, Phase 3 Study
por: Ling, Walter, et al.
Publicado: (2019)

Monthly Extended-Release Risperidone (RBP-7000) in the Treatment of Schizophrenia: Results From the Phase 3 Program
por: Andorn, Anne, et al.
Publicado: (2019)

Recovery From Opioid Use Disorder (OUD) After Monthly Long-acting Buprenorphine Treatment: 12-Month Longitudinal Outcomes From RECOVER, an Observational Study
por: Ling, Walter, et al.
Publicado: (2020)

Once-Monthly Subcutaneously Administered Risperidone in the Treatment of Schizophrenia: Patient Considerations
por: Tchobaniouk, Lesia V, et al.
Publicado: (2019)

ONCE DAILY RISPERIDONE IN TREATMENT OF SCHIZOPHRENIA
por: Agarwal, Vivek, et al.
Publicado: (2001)

Measuring recovery in opioid use disorder: clinical utility and psychometric properties of the Treatment Effectiveness Assessment
por: Ling, Walter, et al.
Publicado: (2019)

Continued Posttrial Benefits of Buprenorphine Extended Release: RECOVER Study Findings
por: Boyett, Brent, et al.
Publicado: (2023)

Reanalysis of a Phase 3 Trial of a Monthly Extended-Release Risperidone Injection for the Treatment of Acute Schizophrenia
por: Le Moigne, Anne, et al.
Publicado: (2021)

Maintenance therapy with once-monthly administration of long-acting injectable risperidone in patients with schizophrenia or schizoaffective disorder: a pilot study of an extended dosing interval
por: Gharabawi, Georges M, et al.
Publicado: (2007)

Real-World Analysis of Switching Patients with Schizophrenia from Oral Risperidone or Oral Paliperidone to Once-Monthly Paliperidone Palmitate
por: Patel, Charmi, et al.
Publicado: (2019)

Efficacy and safety of once-monthly Risperidone ISM(®) in schizophrenic patients with an acute exacerbation
por: Correll, Christoph U., et al.
Publicado: (2020)

RISPERIDONE IN INDIAN PATIENTS WITH SCHIZOPHRENIA
por: Duggal, Harpreet S., et al.
Publicado: (1999)

RISPERIDONE IN INDIAN PATIENTS WITH SCHIZOPHRENIA
por: Agarwal, A.K., et al.
Publicado: (1998)

RISPERIDONE IN SCHIZOPHRENIA
por: Agashe, Mohan, et al.
Publicado: (1999)

RISPERIDONE IN SCHIZOPHRENIA
por: Kumar, P.N. Suresh
Publicado: (1999)

Treating Opioid Use Disorder With a Monthly Subcutaneous Buprenorphine Depot Injection: 12-Month Safety, Tolerability, and Efficacy Analysis
por: Andorn, Anne C., et al.
Publicado: (2020)

Healthcare Resource Utilization and Costs Among Patients With Schizophrenia Switching From Oral Risperidone/Paliperidone to Once-Monthly Paliperidone Palmitate: A Veterans Health Administration Claims Analysis
por: Patel, Charmi, et al.
Publicado: (2020)

COMPARATIVE EFFICACY OF CENTBUTINDOLE & RISPERIDONE IN SCHIZOPHRENIA
por: Chandra, R., et al.
Publicado: (2002)

Risperidone Associated Paralytic Ileus in Schizophrenia
por: Ramamourthy, Parthasarathy, et al.
Publicado: (2013)

Sexual dysfunction in patients with schizophrenia treated with conventional antipsychotics or risperidone
por: Liu-Seifert, Hong, et al.
Publicado: (2009)

Risperidone improves interpersonal perception and executive function in patients with schizophrenia
por: Zhou, Zhenhe, et al.
Publicado: (2016)

A double-blind randomized trial between risperidone and haloperidol in drug-naive patients with paranoid schizophrenia
por: Sagar, K.J. Vijay, et al.
Publicado: (2005)

Once-monthly paliperidone injection for the treatment of schizophrenia
por: Bishara, Delia
Publicado: (2010)

Effects of Continuing Oral Risperidone vs. Switching from Risperidone to Risperidone Long-Acting Injection on Cognitive Function in Stable Schizophrenia Patients: A Pilot Study
por: Hori, Hikaru, et al.
Publicado: (2018)

Projecting the economic outcomes of switching patients with schizophrenia from oral atypical antipsychotics to once-monthly, once-every-3-months, and once-every-6-months paliperidone palmitate
por: Morrison, Laura, et al.
Publicado: (2023)

Clinical utility of the risperidone formulations in the management of schizophrenia
por: Madaan, Vishal, et al.
Publicado: (2011)

Long-acting injectable risperidone in partially adherent and nonadherent patients with schizophrenia
por: Louzã, Mário Rodrigues, et al.
Publicado: (2011)

Risperidone Long-Acting Injection: Safety and Efficacy in Elderly Patients with Schizophrenia
por: Catalán, Rosa, et al.
Publicado: (2011)

Clozapine and risperidone influence on cortisol and estradiol levels in male patients with schizophrenia
por: Piriu, G, et al.
Publicado: (2015)

Effect of Aripiprazole on Cognitive Function and Hyperprolactinemia in Patients with Schizophrenia Treated with Risperidone
por: Lee, Bong Ju, et al.
Publicado: (2013)

Correlation of hair risperidone concentration and serum level among patients with schizophrenia
por: Sun, Xiujia, et al.
Publicado: (2019)

Sexual dysfunction in male schizophrenia remitted patients treated with risperidone and olanzapine
Publicado: (2022)

Transitioning from Once-Monthly to Once-Every-3-Months Paliperidone Palmitate Among Veterans with Schizophrenia
por: El Khoury, Antoine C, et al.
Publicado: (2021)

Adherence, Healthcare Resource Utilization, and Costs in Medicaid Beneficiaries with Schizophrenia Transitioning from Once-Monthly to Once-Every-3-Months Paliperidone Palmitate
por: Emond, Bruno, et al.
Publicado: (2018)

Paliperidone ER and oral risperidone in patients with schizophrenia: a comparative database analysis
por: Turkoz, Ibrahim, et al.
Publicado: (2011)

Abnormalities in large scale functional networks in unmedicated patients with schizophrenia and effects of risperidone
por: Kraguljac, Nina Vanessa, et al.
Publicado: (2015)

A case report of eosinophilia associated with risperidone withdrawl in a patient with schizophrenia
por: Giourou, E., et al.
Publicado: (2022)

Metabolic biomarkers of risperidone-induced weight gain in drug-naïve patients with schizophrenia
por: Qiu, Yuying, et al.
Publicado: (2023)

An observational cohort study of extended dosing (once every 2 weeks or once monthly) regimens with darbepoetin alfa in patients with chronic kidney disease not on dialysis: the EXTEND study
por: Galle, Jan-Christoph, et al.
Publicado: (2012)

Treatment of Schizophrenia With Long-Acting Fluphenazine, Haloperidol, or Risperidone
por: Olfson, Mark, et al.
Publicado: (2007)

Cannot write session to /tmp/vufind_sessions/sess_vspinefobstiqipt5ie0v6mvlo